Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer.

Yalan Dai,Liqiong Yang, Abass Sakandar,Duoli Zhang,Fukuan Du,Xinyi Zhang,Linglin Zou,Yueshui Zhao,Jigang Wang,Zhenhua Zhang,Xu Wu,Mingxing Li, Xiao Ling,Lei Yu, Lishu Dong,Jing Shen,Zhangang Xiao,Qinglian Wen

Frontiers in oncology（2022）

引用 0|浏览5

暂无评分

摘要

Briefly, our work establishes and validates an 11-immune escape risk model, and five core prognostic factors that are mined deeply from this model, and elucidates in detail that Vemurafenib suppresses breast cancer by targeting the PI3K/AKT signaling pathway to inhibit the immune escape biomarker BCL2A1, confirms the validity of the prognostic model, and provides corresponding targeted agents to guide individualized treatment of BC patients.

查看译文

关键词

BCL2A1,Immune escape,PI3K/Akt signaling pathway,bioinformatics,biomarker,breast cancer,prognostic model,vemurafenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要